Reneo Pharmaceuticals, Inc. 2022 Form 10-K Summary
Filing identification: The provided filing is for Reneo Pharmaceuticals, Inc., not Onkure Therapeutics, Inc. It covers the fiscal year ended December 31, 2022, and was filed March 27, 2023. The filing is an annual report rather than a quarterly report, although the requested period is identified as 2022 Q4.
Business Context and Reporting Period
Reneo is a clinical-stage pharmaceutical company developing mavodelpar (REN001), an oral, selective PPARδ agonist intended to treat rare genetic mitochondrial diseases, primarily primary mitochondrial myopathy (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD). Mavodelpar is the company’s only product candidate, and no product has been approved for commercial sale.
The company has received U.S. orphan drug designations for PMM and LC-FAOD, European orphan designations for MELAS and LCHAD deficiency, and FDA Fast Track designation for PMM and LC-FAOD due to LCHAD deficiency.
Financial Performance and Key Metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | No product revenue | No product revenue | Not applicable |
| Research and development expense | $37.7 million | $28.2 million | +$9.5 million |
| General and administrative expense | $16.1 million | $11.6 million | +$4.5 million |
| Total operating expenses | $53.8 million | $39.8 million | +$14.0 million |
| Loss from operations | $53.8 million | $39.8 million | +$14.0 million loss |
| Other income | $1.9 million | $0.05 million | +$1.8 million |
| Net loss | $52.0 million | $39.8 million | +$12.2 million loss |
| Basic and diluted net loss per share | $2.12 | $2.19 | Loss per share improved |
| Net cash used in operating activities | $47.4 million | $38.0 million | +$9.4 million use |
| Cash, cash equivalents and short-term investments | $101.2 million | $147.7 million | -$46.5 million |
Operating expenses increased primarily because of higher clinical, manufacturing and personnel costs associated with the STRIDE and STRIDE AHEAD studies. General and administrative expense also increased due to higher outside professional services, facility costs and headcount. Higher interest rates contributed to the increase in other income.
At December 31, 2022, cash and cash equivalents were $19.9 million and short-term investments were $81.2 million. Total assets were $108.2 million, total liabilities were $8.2 million and stockholders’ equity was $100.0 million. The filing does not disclose material debt; disclosed liabilities primarily comprise accounts payable, accrued expenses, lease liabilities and a performance award.
Net cash used in investing activities was $57.8 million, primarily reflecting purchases of short-term investments. Net cash provided by financing activities was $0.5 million, primarily from equity-plan activity and limited sales under the at-the-market facility. The company had no meaningful operating margin because it had no revenue and incurred operating losses.
Material Changes Versus the Prior Comparable Period
- Net loss increased from $39.8 million to $52.0 million.
- Research and development expense increased 34%, from $28.2 million to $37.7 million.
- General and administrative expense increased 39%, from $11.6 million to $16.1 million.
- Operating cash burn increased from $38.0 million to $47.4 million.
- Liquidity declined from $147.7 million at December 31, 2021 to $101.2 million at December 31, 2022.
- Interest income increased materially because of higher interest rates.
- The company adopted lease accounting guidance, recognizing operating lease right-of-use assets and lease liabilities.
- No vTv Therapeutics milestone payment was achieved or recorded in 2022, compared with a $2.0 million milestone payment recorded in 2021.
Clinical Outlook, Guidance and Risks
Management reported that the STRIDE pivotal Phase 2b trial achieved its target enrollment of 200 patients in March 2023. The trial evaluates 100 mg of mavodelpar once daily for 24 weeks in adults with PMM due to mitochondrial DNA defects, with the 12-minute walk test as the primary efficacy endpoint. Topline results were anticipated in the fourth quarter of 2023.
STRIDE AHEAD is an open-label, long-term safety study outside the United States. Management stated that positive STRIDE and STRIDE AHEAD results could support planned U.S. and European marketing applications in 2024, although regulatory approval is not assured.
Reneo intends to continue developing mavodelpar for selected LC-FAOD genotypes, including LCHAD, and was working with regulators on the next clinical trial’s design, patient population and endpoints. The company also expects to conduct two-year carcinogenicity studies in rats and mice, with results expected in the fourth quarter of 2023.
The audited financial statements include an explanatory matter stating that recurring losses and negative operating cash flows raise substantial doubt about the company’s ability to continue as a going concern for twelve months after issuance of the financial statements. Management expects to seek additional equity or debt financing, collaborations, strategic alliances or licensing arrangements. The filing states that existing liquidity was expected to fund operating expenses and capital requirements through planned near-term clinical milestones, but additional capital will be required.
Key contingencies and risks include clinical-trial failure or delay, limited enrollment in rare-disease studies, regulatory uncertainty, potential safety or carcinogenicity findings, reliance on contract research organizations and manufacturers, single-source clinical supply, dependence on the vTv Therapeutics license, intellectual-property challenges, reimbursement uncertainty, dilution from future financing, and volatility or disruption in financial markets. The company also disclosed that it maintained operating accounts at Silicon Valley Bank and could experience payment disruptions following the bank’s March 2023 closure, although the FDIC subsequently announced that SVB deposits were fully insured.
The vTv license requires potential development and regulatory milestone payments of up to $64.5 million, sales-based milestones of up to $30.0 million and tiered royalties generally ranging from mid-single-digit to low-teen percentages of net sales. No material legal proceedings were pending at the filing date.
Important Facts an Investor Should Verify
- Confirm that the filing belongs to Reneo Pharmaceuticals, Inc. and not Onkure Therapeutics, Inc.
- Verify the going-concern disclosure and the company’s expected cash runway after December 31, 2022.
- Review final STRIDE results and determine whether the primary endpoint and key secondary endpoints were achieved.
- Assess the status and results of STRIDE AHEAD and the timing and content of any FDA or EMA submissions.
- Review the two-year carcinogenicity study results and any resulting regulatory restrictions.
- Track additional financing, ATM sales and potential dilution; approximately $18.8 million remained available under the ATM facility as of March 21, 2023.
- Evaluate clinical supply, manufacturing, licensing and royalty obligations under the vTv Therapeutics agreement.
- Confirm the company’s liquidity, investment portfolio and banking arrangements following the Silicon Valley Bank disruption.